100 related articles for article (PubMed ID: 25951802)
1. Coencapsulation of hydrophobic and hydrophilic antituberculosis drugs in synergistic Brij 96 microemulsions: a biophysical characterization.
Kaur G; Mehta SK; Kumar S; Bhanjana G; Dilbaghi N
J Pharm Sci; 2015 Jul; 104(7):2203-12. PubMed ID: 25951802
[TBL] [Abstract][Full Text] [Related]
2. Probing location of anti-TB drugs loaded in Brij 96 microemulsions using thermoanalytical and photophysical approach.
Kaur G; Mehta SK
J Pharm Sci; 2014 Mar; 103(3):937-44. PubMed ID: 24425102
[TBL] [Abstract][Full Text] [Related]
3. Entrapment of multiple anti-Tb drugs in microemulsion system: quantitative analysis, stability, and in vitro release studies.
Mehta SK; Kaur G; Bhasin KK
J Pharm Sci; 2010 Apr; 99(4):1896-911. PubMed ID: 19894276
[TBL] [Abstract][Full Text] [Related]
4. Formulation of Tyloxapol niosomes for encapsulation, stabilization and dissolution of anti-tubercular drugs.
Mehta SK; Jindal N
Colloids Surf B Biointerfaces; 2013 Jan; 101():434-41. PubMed ID: 23010052
[TBL] [Abstract][Full Text] [Related]
5. Location of anti-TB drugs and microstructural changes in organized surfactant media using optical properties.
Mehta SK; Kaur G
J Colloid Interface Sci; 2011 Apr; 356(2):589-97. PubMed ID: 21292277
[TBL] [Abstract][Full Text] [Related]
6. Artificial neural networks to optimize formulation components of a fixed-dose combination of rifampicin, isoniazid and pyrazinamide in a microemulsion.
Glass BD; Agatonovic-Kustrin S; Wisch MH
Curr Drug Discov Technol; 2005 Sep; 2(3):195-201. PubMed ID: 16472228
[TBL] [Abstract][Full Text] [Related]
7. Tween-embedded microemulsions--physicochemical and spectroscopic analysis for antitubercular drugs.
Mehta SK; Kaur G; Bhasin KK
AAPS PharmSciTech; 2010 Mar; 11(1):143-53. PubMed ID: 20087697
[TBL] [Abstract][Full Text] [Related]
8. A mesoporous silicon/poly-(DL-lactic-co-glycolic) acid microsphere for long time anti-tuberculosis drug delivery.
Xu W; Wei X; Wei K; Cao X; Zhong S
Int J Pharm; 2014 Dec; 476(1-2):116-23. PubMed ID: 25271077
[TBL] [Abstract][Full Text] [Related]
9. Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinamide toxicity.
Tostmann A; Boeree MJ; Peters WH; Roelofs HM; Aarnoutse RE; van der Ven AJ; Dekhuijzen PN
Int J Antimicrob Agents; 2008 Jun; 31(6):577-80. PubMed ID: 18358703
[TBL] [Abstract][Full Text] [Related]
10. Improved Stability of Tuberculosis Drug Fixed-Dose Combination Using Isoniazid-Caffeic Acid and Vanillic Acid Cocrystal.
Battini S; Mannava MKC; Nangia A
J Pharm Sci; 2018 Jun; 107(6):1667-1679. PubMed ID: 29462633
[TBL] [Abstract][Full Text] [Related]
11. Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons.
Liu L; Xu Y; Shea C; Fowler JS; Hooker JM; Tonge PJ
J Med Chem; 2010 Apr; 53(7):2882-91. PubMed ID: 20205479
[TBL] [Abstract][Full Text] [Related]
12. Transdermal delivery of hydrophobic and hydrophilic local anesthetics from o/w and w/o Brij 97-based microemulsions.
Junyaprasert VB; Boonme P; Songkro S; Krauel K; Rades T
J Pharm Pharm Sci; 2007; 10(3):288-98. PubMed ID: 17727792
[TBL] [Abstract][Full Text] [Related]
13. Stability of isoniazid, rifampin and pyrazinamide in suspensions used for the treatment of tuberculosis in children.
Seifart HI; Parkin DP; Donald PR
Pediatr Infect Dis J; 1991 Nov; 10(11):827-31. PubMed ID: 1749695
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic explanation to the catalysis by pyrazinamide and ethambutol of reaction between rifampicin and isoniazid in anti-TB FDCs.
Bhutani H; Singh S; Jindal KC; Chakraborti AK
J Pharm Biomed Anal; 2005 Oct; 39(5):892-9. PubMed ID: 15978767
[TBL] [Abstract][Full Text] [Related]
15. Formulation and statistical optimization of a novel crosslinked polymeric anti-tuberculosis drug delivery system.
du Toit LC; Pillay V; Danckwerts MP; Penny C
J Pharm Sci; 2008 Jun; 97(6):2176-207. PubMed ID: 17879985
[TBL] [Abstract][Full Text] [Related]
16. Co-encapsulation of isoniazid and rifampicin in liposomes and characterization of liposomes by derivative spectroscopy.
Gürsoy A; Kut E; Ozkirimli S
Int J Pharm; 2004 Mar; 271(1-2):115-23. PubMed ID: 15129978
[TBL] [Abstract][Full Text] [Related]
17. Mixed surfactant (altering chain length and head group) aggregates as an effective carrier for tuberculosis drug.
Kumar A; Rekha ; Kansal SK; Ibhadon AO; Mehta SK
Chem Phys Lipids; 2018 Sep; 215():11-17. PubMed ID: 30033376
[TBL] [Abstract][Full Text] [Related]
18. Compatibility Between Four Anti-TB Drugs and Tablet Excipients Determined By Microcalorimetry.
Aucamp M; Liebenberg W; Okaecwe T; Geldenhuys M; Stieger N
Pharmazie; 2019 Jun; 74(6):350-351. PubMed ID: 31138372
[TBL] [Abstract][Full Text] [Related]
19. Encapsulation of Rifampicin in a solid lipid nanoparticulate system to limit its degradation and interaction with Isoniazid at acidic pH.
Singh H; Bhandari R; Kaur IP
Int J Pharm; 2013 Mar; 446(1-2):106-11. PubMed ID: 23410991
[TBL] [Abstract][Full Text] [Related]
20. Probing the microstructure of nonionic microemulsions with ethyl oleate by viscosity, ROESY, DLS, SANS, and cyclic voltammetry.
Kaur G; Chiappisi L; Prévost S; Schweins R; Gradzielski M; Mehta SK
Langmuir; 2012 Jul; 28(29):10640-52. PubMed ID: 22720716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
